Mondaq UK: Food, Drugs, Healthcare, Life Sciences
Mayer Brown
The eligibility is based on the risk of EU residents becoming affected by the disease.
Mayer Brown
Two important developments occurred in mid-November 2016 for the pharmaceutical industry in Europe: the European Commission published a revised guideline on orphan medicinal products...
Jones Day
Two companies have applied to the Food Standards Agency ("FSA") for approval to market their novel food products in the EU under the Novel Food Regulation (EC) 258/97.
Clyde & Co
A 'Never Event' is a term used by the NHS to describe serious patient safety incidents which are largely or wholly preventable.
Deloitte
Many health plans are raising the bar for value as they try to rein in drug spending.
Deloitte
After studying bioengineering and completing a PhD in the San Francisco Bay Area and a two-year postdoctoral research fellowship in London, Mark has spent the past four years analysing global health policy.
Deloitte
Our recent report Vital Signs: how to deliver better healthcare across Europe highlighted, as one of our vital signs, patient engagement and empowerment.
Deloitte
This week's blog is from Rachel Alsop, one of our colleagues in our strategy consulting team who spends some of her own time volunteering with the humanitarian mapping charity, MapAction.
Taylor Wessing
Paul England discusses what recent events tell us about the intended role of the life sciences sector in the post-Brexit economy.
Clyde & Co
The NHS Litigation Authority has recently launched a programme of reform for its main indemnity scheme, the Clinical Negligence Scheme for Trusts (CNST).
Deloitte
The pharmaceutical industry continues to face regulatory and reimbursement hurdles weighing on the research and development returns of pharmaceutical firms this year.
Gill Jennings & Every
The UK's National Food Crime Unit recently estimated that piracy could account for more than one billion pounds of annual UK food and drink trade.
Clyde & Co
What happens if a patient undergoes surgery earlier than planned and he suffers an adverse outcome?
Deloitte
Last week's World Antibiotic Awareness Week was aimed at continuing to raise the profile of importance of tackling antimicrobial resistance.
Deloitte
November 14th was World Diabetes Day.i Today in the UK there are some 3.5 million people diagnosed with diabetes and 549,000 people living, unknowingly, with the condition.
Clyde & Co
A doctor must discuss all reasonable alternative treatment options with the patient, according to the Supreme Court in Montgomery v Lanarkshire Health Board.
Deloitte
The pharmaceutical industry is facing a 'tidal wave' of complex age and behaviour related diseases creating increased economic, scientific and delivery risks.
Deloitte
This week we launched our report Primary care today and tomorrow: Adapting to survive, which provides an update on our understanding of the developments and challenges in primary care...
Deloitte
Whilst enjoying a creamy pint of draft Guinness, have you ever wondered about its journey from brewery to bar.
Deloitte
In January, Deloitte published its 2017 Global healthcare sector outlook, which confirms that the challenges of providing and funding health care around the globe have remained fairly persistent...
Latest Video
Most Popular Recent Articles
Abel & Imray
On 1 February 2017 the Board of Appeal of the EPO upheld the revocation of Bristol-Myers Squibb's (BMS) patent for anti-cancer drug dasatinib due to a lack of inventive step.
Abel & Imray
The inclusion of a disclaimer, where subject matter is carved out from the scope of a patent claim by means of a negative feature is not explicitly allowed for in the European Patent Convention (EPC).
Abel & Imray
Additional post-filing data is often crucial to confirm the technical effect of pharmaceutical patents. On 1 February 2017 the Board of Appeal of the European Patent Office will be deciding the fate of Bristol-Myers Squibb's (BMS) patent directed to dasatinib.
Abel & Imray
A SPC is a unique intellectual property right that can give up to 5 years additional protection for a medicinal or veterinary product or a plant protection product covered by a patent after the patent term has expired.
Deloitte
In January, Deloitte published its 2017 Global healthcare sector outlook, which confirms that the challenges of providing and funding health care around the globe have remained fairly persistent...
Deloitte
Many health plans are raising the bar for value as they try to rein in drug spending.
Deloitte
After studying bioengineering and completing a PhD in the San Francisco Bay Area and a two-year postdoctoral research fellowship in London, Mark has spent the past four years analysing global health policy.
Clyde & Co
A 'Never Event' is a term used by the NHS to describe serious patient safety incidents which are largely or wholly preventable.
Jones Day
Two companies have applied to the Food Standards Agency ("FSA") for approval to market their novel food products in the EU under the Novel Food Regulation (EC) 258/97.
Gowling WLG
Nowhere are concerns over the potential impact of Brexit on transatlantic business relations being more keenly felt than among US food and drink businesses.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Up-coming Events Search
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners
In association with